Takeda Calls FCA Suit Over Unsafe Drug Interactions Baseless

Law360, New York (May 14, 2012, 1:49 PM EDT) -- Takeda Pharmaceutical Co. Ltd. on Friday urged a judge to dismiss a former contractor’s False Claims Act suits accusing the drugmaker of purposely concealing unsafe drug interactions in four treatments for gout, heartburn and diabetes, saying she hasn’t stated a valid claim.

Takeda told a Massachusetts federal judge that Dr. Helen Ge’s assertions that the drugmaker failed to adequately notify the U.S. Food and Drug Administration of potential adverse effects of its gout treatment Uloric, gastroesophogeal reflux disease treatments Dexilant and Prevacid and diabetes treatment Actos...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

United States of America et al v. Takeda Pharmaceutical Company Limited, et al


Case Number

1:11-cv-10343

Court

Massachusetts

Nature of Suit

Other Statutory Actions

Judge

F. Dennis Saylor, IV

Date Filed

March 1, 2011


Case Title

United States of America et al v. Takeda Pharmaceutical Company Limited et al


Case Number

1:10-cv-11043

Court

Massachusetts

Nature of Suit

Other Statutory Actions

Judge

F. Dennis Saylor, IV

Date Filed

June 18, 2010

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.